ObjectiveDrug-induced movement disorders (DIMDs) may occur in patients treated with antipsychotics. The CommonGround Program supports the recovery and healing of psychiatric outpatients through tools which facilitate better patient-doctor communication regarding psychiatric symptoms, DIMDs, and the effectiveness of treatment.MethodsPatients responses to CommonGround’s web-based waiting-room questionnaire were analyzed in patients who responded yes to having concerns about developing DIMDs (MD-YES) and those who responded no to this question (MD-NO). These groups were compared descriptively to assess the potential effects of DIMD concerns on self-reported functioning and beliefs about prescribed psychiatric medications.ResultsOf 7874 responding patients, 312 (4.0%) and 7562 (96.0%) were in the MD-YES and MD-NO subgroups, respectively. A higher percentage of MD-YES patients reported poor / not so good ability to keep up with daily responsibilities (21.2% vs 15.2% vs MD-NO), along with low energy levels (37.1% vs 26.3% for MD-NO), bothersome thoughts/beliefs/fears (30.5% vs 16.0%), and nervousness/anxiety (35.3% vs 27.5%) all / most of the time. MD-YES patients were also more likely to wonder about stopping their medications (9.3% vs 0.6% for MD-NO) and were concerned about side effects such as sleepiness (31.4% vs 3.9%) and weight gain (37.2% vs 5.7%).ConclusionPatients from community mental health centers who were concerned about developing DIMDs tended to express problems with daily functioning and concerns about their psychiatric medications. For these patients, recognizing their fears and concerns may help clinicians discuss treatment options for DIMDs, which could increase patient confidence, encourage adherence to current psychiatric medications, and potentially improve outcomes.

中文翻译：

---

社区心理健康中心 (CMHC) 患者对药物性运动障碍的担忧：对功能和治疗信念的影响

目的 接受抗精神病药物治疗的患者可能会出现药物诱发的运动障碍（DIMDs）。CommonGround 计划通过工具支持精神科门诊患者的康复和康复，这些工具有助于就精神症状、DIMD 和治疗有效性进行更好的医患沟通。担心发展 DIMDs (MD-YES) 和那些对此问题没有回答的人 (MD-NO)。对这些组进行描述性比较，以评估 DIMD 担忧对自我报告的功能和对处方精神科药物的信念的潜在影响。结果在 7874 名有反应的患者中，312 名（4.0%）和 7562 名（96.0%）处于 MD-YES 和 MD-没有亚组，分别。更高比例的 MD-YES 患者报告说，他们无法/不太好地跟上日常职责（21.2% vs 15.2% vs MD-NO），以及低能量水平（37.1% vs 26.3% MD-NO），烦人的想法/信念/恐惧（30.5% vs 16.0%）和紧张/焦虑（35.3% vs 27.5%）所有/大部分时间。MD-YES 患者也更有可能对停药感到疑惑（9.3% 对 MD-NO 为 0.6%），并担心诸如嗜睡（31.4% 对 3.9%）和体重增加（37.2% 对 5.7%）等副作用).结论来自社区精神卫生中心的担心发展为 DIMD 的患者倾向于表达日常功能问题和对其精神科药物的担忧。对于这些患者，认识到他们的恐惧和担忧可能有助于临床医生讨论 DIMD 的治疗方案，